Navigation Links
Lexicon Files Investigational New Drug Application for LX2931 as a Potential Treatment for Rheumatoid Arthritis
Date:11/12/2007

clinical programs, the LX2931 target enzyme was identified through Lexicon's gene knockout program, Genome5000(TM). Knockout mice lacking this enzyme had a significantly decreased number of circulating lymphocytes and were resistant to inflammation in a wide range of assays modeling processes involved in the development of arthritis and other autoimmune conditions. Because inappropriate activation of lymphocytes is associated with autoimmune disorders, including rheumatoid arthritis, reduction of lymphocyte buildup at sites of disease activity holds promise as a new therapeutic mechanism. Preclinical studies with LX2931 showed a robust and reproducible reduction of inflammation in animal models of arthritis. Additionally, LX2931-treated animals showed a rapid, dose-dependent reduction in peripheral lymphocyte counts.

About Lexicon

Lexicon is a biopharmaceutical company focused on the discovery and development of breakthrough treatments for human disease. Lexicon currently has development programs underway for such areas of major unmet medical need as irritable bowel syndrome, cognitive disorders, and autoimmune diseases. The company has used its proprietary gene knockout technology to discover more than 100 promising drug targets and create an extensive pipeline of clinical and preclinical programs in the therapeutic areas of diabetes and obesity, cardiovascular disease, psychiatric and neurological disorders, cancer, immune system disorders and ophthalmic disease. Lexicon's drug discovery system has been so productive that Lexicon plans to move ten drug candidates into human clinical trials by the end of 2010. This strategic initiative is referred to as the 10to10 program. To advance the development and commercialization of its programs, Lexicon is working both independently and through collaborators including Bristol-Myers Squibb Company, Genentech, Inc. and N.V. Organon. For additional information about Lexicon and its programs, please visit

SOURCE Lexicon Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Lexicon to Present Research Results at American Chemical Society Meeting Regarding Target of LX1031 Drug Candidate
2. Lexicon Reports Initial Clinical Trial Results for LX1031, an Investigational New Drug for Irritable Bowel Syndrome
3. Quark Pharmaceuticals Files Patent Application Covering Novel Chemical Modifications to its RNAi Molecules
4. Lilly Files for European Approval of ALIMTA(R) (pemetrexed for injection) for First-Line Treatment of Non-Small Cell Lung Cancer
5. AngioGenex Files Patent on First Small Molecule Id-Inhibitors for the Treatment of Cancer
6. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
7. A Worldwide Phase III Clinical Trial Seeks U.S. Patients to Explore Investigational Drug Phenoxodiol
8. Ardea Biosciences, Inc. Announces Completion of Phase 1 Clinical Trials of Novel Investigational HIV Drug RDEA806
9. ECLIPSE Data on Effects of Otsukas Investigational Novel Treatment, Tolvaptan, on Advanced Heart Failure Patients Hemodynamics and Urine Output Featured in Heart Failure Society of Americas Late Breaking Trials
10. Replidynes Investigational Antibacterial Agent REP3123 Prevents Sporulation in Clostridium difficile
11. Replidynes Investigational Antibacterial Agent REP3123 Prevents Toxin Production in Clostridium difficile
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... 2014   ViaDerma, Inc. (OTCQB: VDRM), ... products to market, has recently released a revolutionary ... a topical liquid tetracycline-based antibiotic that uses a ... oral medication active ingredients into topical drugs. The ... antibiotic to help prevent skin infection in minor ...
(Date:10/30/2014)... , Oct. 30, 2014  Nektar Therapeutics (Nasdaq: ... for the third quarter ended September 30, 2014 on ... financial markets. Howard Robin , president and chief ... the results beginning at 5:00 p.m. Eastern Time (ET)/2:00 ... release and a live audio-only Webcast of the conference ...
(Date:10/30/2014)... --  BioLife Solutions , Inc. (NASDAQ: BLFS ... clinical grade hypothermic storage and cryopreservation ... for cells and tissues, today announced today that ... released on Thursday, November 6, 2014, and that the ... at 1:30 p.m. PST that afternoon. Management will provide ...
Breaking Medicine Technology:ViaDerma, Inc. Lead Product TetraStem Shown Effective in Fighting Staph Infections including MRSA 2ViaDerma, Inc. Lead Product TetraStem Shown Effective in Fighting Staph Infections including MRSA 3Nektar to Announce Financial Results for the Third Quarter 2014 on Thursday, November 6, 2014, After Close of U.S.-Based Financial Markets 2BioLife Solutions to Report Financial Results for Third Quarter 2014 and Provide Business Update on November 6, 2014 2
... Replacing both knees in one surgery, or simultaneous ... fewer prosthetic joint infections as well as other revision ... total knee replacements performed in two separate procedures. However, ... of adverse cardiovascular outcomes within 30 days, according to ...
... Zimmer Holdings, Inc. (NYSE: ZMH ; SIX: ZMH), a ... of the first patients treated with Zimmer MotionLoc™ Screws ... Screw is Zimmer Trauma,s latest advancement in locking plate technology and ... NCB ® Polyaxial Locking Plate System.   The ...
Cached Medicine Technology:Two Knee Replacements May Be Better Than One 2Zimmer Announces Early Clinical Success of Zimmer® MotionLoc™ Screw Implantation 2Zimmer Announces Early Clinical Success of Zimmer® MotionLoc™ Screw Implantation 3
(Date:10/30/2014)... Graphics, coding, typography and search engine ... craft of web design and require thorough knowledge to ... solution to create a website can be as easy ... customer reviews and Facebook posts all accumulate on a ... next evolution of how a business can develop a ...
(Date:10/30/2014)... Austin, TX (PRWEB) October 30, 2014 ... is gifting PreD Store shoppers with a ... taken before meals to reduce post-meal blood sugar spikes. ... overall health is an important part of a diabetes ... on orders will receive one complimentary tube of sugardown. ...
(Date:10/30/2014)... Haelle HealthDay Reporter , ... 100 genes have been identified that appear linked to ... researchers say they are on their way to discovering ... the disorder. Autism spectrum disorders include a range ... and repetitive behaviors. An estimated one in 68 U.S. ...
(Date:10/30/2014)... 2014 Horse Sense & Sensitivity ... to special needs individuals in the Jacksonville area, will ... 15 from 10-2:00 p.m. at Bailey's Farm (2202 Bishop ... the public and is designed to raise awareness and ... the HSS Round-Up is free. Ticket purchases will be ...
(Date:10/30/2014)... South Carolina (PRWEB) October 30, 2014 ... and should be more vigorously exercised to help maintain ... recently authored the book ‘Dementia Express: Lose Your Memory ... book uses counterintuitive reasoning and sometimes conflicting attitudes to ... course for the mind, a reader must decipher the ...
Breaking Medicine News(10 mins):Health News:Facebook Websites In Thirty-Seconds 2Health News:PreDiabetes Treatment Company Offers PreD Store Shoppers Supplements to Support Healthy Blood Sugar 2Health News:Discovery of 100-Plus Genes Tied to Autism May Improve Treatments 2Health News:Discovery of 100-Plus Genes Tied to Autism May Improve Treatments 3Health News:Horse Sense & Sensitivity, Jacksonville Non-profit, To Hold 2nd Annual Round-Up 2Health News:‘Dementia Express’ Offers Contradictory and Sometimes Reverse Thinking, All to Keep its Reader on Their Toes With an Active Mind. 2
... as the incidence is likely to increase in the ... the course of Alzheimer's disease. There is a special ... messenger and this chemical//is regulated by a drug called ... enabled by the chemical glutamate. This happens when glutamate ...
... indicates lack of protein to development of cancer. Cells without ... either kill a cell or keep it from growing. However ... are able to multiply creating tumors. Researchers indicated that loss ... a normal cell the chance to change into a cancer ...
... In a recent study which examined the snoring habits ... them. People with chronic(15 headaches per month) daily headache ... chronic snorers than the people with occasional(104 headaches per ... and 65. When the researchers analysed people, those with ...
... indicates that Negative exercise electrocardiograph tests should ... of hypertensive patients with chest pain. Even ... risk, positive findings could not distinguish levels ... pharmacological stress echocardiography yielded diagnostic and prognostic ...
... first country to contain its SARS outbreak. Vietnam had five ... Hanoi's international hospital. There was about sixty three people affected ... there by reducing the rate of infection and keeping SARS ... have been reported from Vietnam since April 8.// The country ...
... in India went up to 10, authorities are not confident ... shown a far higher recovery rate than the rest of ... medical care provided to SARS patients. Even what we call ... are only between 60 and 65 per cent accurate according ...
Cached Medicine News:
BD Vacutainer® Fluoride Tubes - Glass...
VACUETTE Trace Element tubes - Ridged (safety screw cap) are designed to test trace elements such as Cu, Zn, Pb, etc....
Inquire...
VACUETTE paediatric tubes have decreased sample volumes and are ideal for small childrens' veins and geriatric patients....
Medicine Products: